(MENAFN- ProactiveInvestors)Clinigen (LON:CLIN) said its Idis arm will manage a programme that will give young children with brain cancer access to a treatment not yet commercially available in certain countries. Idis is teaming up with United Therapeutics Corporation developer of UNITUXIN which is given via injection. The programme will help adolescents and children as young as 12 months with neuroblastoma that fall into the high risk category. "Neuroblastoma is a devastating disease which seriously endangers young lives and where there are few treatment options available' said Idis managing director Simon Estcourt. 'As partners to United Therapeutics we can leverage our global distribution network and regulatory expertise to deliver UNITUXIN injection to the physicians on behalf of their young patients wherever and whenever it is needed fast."
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.